RE:Candel Therapeutics not addressing metastatic PDACAfter a protocol amendment in 2022, Candel Therapeutics discontinued the enrollment of patients with locally advanced PDAC to focus exclusively on those with the lesser challenging borderline resectable disease.
Locally advanced PDAC is non-metastatic however LA-PDAC involves the local invasion of adjacent structures.
Patients with locally advanced pancreatic cancer may undergo surgery to remove a portion of the tumor, while others rely on nonsurgical therapies to help reduce symptoms and slow the spread of cancerous cells. Locally advanced pancreatic cancer is typically associated with patients in stage 3 of the disease as determined by the TNM (tumor, nodes and metastasis) grading system.